Shell Asset Management Co. Has $377,000 Stake in Five Prime Therapeutics, Inc. (FPRX)
Shell Asset Management Co. continued to hold its position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,534 shares of the biotechnology company’s stock at the end of the second quarter. Shell Asset Management Co.’s holdings in Five Prime Therapeutics were worth $377,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Creative Planning increased its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 54 shares in the last quarter. Laurion Capital Management LP bought a new position in Five Prime Therapeutics during the first quarter valued at about $210,000. Rockefeller Financial Services Inc. bought a new position in Five Prime Therapeutics during the second quarter valued at about $210,000. BlueCrest Capital Management Ltd bought a new position in Five Prime Therapeutics during the first quarter valued at about $254,000. Finally, Arxis Securities LLC bought a new position in Five Prime Therapeutics during the first quarter valued at about $267,000. Institutional investors own 84.36% of the company’s stock.
Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) opened at 27.76 on Wednesday. The stock’s 50 day moving average is $29.24 and its 200 day moving average is $34.38. The firm’s market cap is $776.86 million. Five Prime Therapeutics, Inc. has a 52 week low of $25.97 and a 52 week high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by $0.43. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. During the same period in the prior year, the company earned ($0.49) EPS. Five Prime Therapeutics’s quarterly revenue was down 16.1% on a year-over-year basis. On average, equities research analysts predict that Five Prime Therapeutics, Inc. will post ($5.05) earnings per share for the current fiscal year.
FPRX has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Wednesday, April 26th. Jefferies Group LLC restated a “buy” rating and issued a $52.00 price objective (down previously from $55.00) on shares of Five Prime Therapeutics in a research note on Thursday, August 10th. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, BidaskClub downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Five Prime Therapeutics has an average rating of “Hold” and a consensus target price of $60.80.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.